Comparison · NCT03036124-a4f92aa3
Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure. Trial comparisons, record NCT03036124-a4f92aa3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03036124-a4f92aa3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.161 | 0.147 | 0.176 | wilson | |
| Risk in group 2 | 0.209 | 0.193 | 0.226 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0478 | -0.0698 | -0.0257 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.771 | 0.683 | 0.87 | log | |
| Odds ratio, group 1 over group 2 | 0.727 | 0.627 | 0.843 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dapa 10 mg than on Placebo | 20.9 | 14.3 | 38.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapa 10 mg | Dapagliflozin 10 mg tablets administered orally once daily | 382 | 2,373 | OG000 |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use. | 495 | 2,371 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
- Description
- Secondary
- Time frame
- Up to 27.8 months.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
- NCT number
- NCT03036124
- Phases
- PHASE3
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-09-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03036124?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03036124-a4f92aa3